Bear, interesting post and regarding inflammation and perhaps good for apabetalone?

One thing that struck me in your post was the first line.

BDAZ wrote -"The CANTOS trial results supporting the inflammation hypothesis and presented at ESC 2017 sure roused quite a bit of excitement amongst clinicians and researchers."

I take it this was excitment in a hopeful context. With all of the conferences and presentations done by RVX and my 10 years of holding this stock I do not recall ever hearing anything like that applied to apabetalone or RVX. I don't mean to sound cynical. I still believe I hold shares in a scientific breakthrough and I'll know in the next few years.

Don's favourite phrase when he is presenting is "and we're really excited about that" but I've never seen references to how scientific audiences regarding RVX presentations. I wonder why? Does anyone have any insight to offer on this?

Toinv